API | sarpogrelate

sarpogrelate Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Sarpogrelate is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation, and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis. ^Wikipedia

Chemistry

SMILES: COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1
InChIKey: FFYNAVGJSYHHFO-UHFFFAOYSA-N
Mol. Mass: 429.51
ALogP: 3.2 Partition coefficient
ChEMBL Molecule:
sarpogrelate

More Chemistry

Pharmacology

Mechanisms of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2B (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (12)

Research & Development (12)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Thrombosis

Experimental Indications - Clinical Trial Phases 1-4 (10)

Angina Pectoris (Phase 4)

Blood Viscosity (Phase 4)

Cerebral Infarction (Phase 3)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus (Phase 3)

Diabetic Nephropathies (Phase 4)

Healthy Volunteers (Phase 1)

Hypertension (Phase 1)

Peripheral Arterial Disease (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 20
# of Trial Organizations: 12

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue